Biomarker-Driven Lung Cancer | Clinical

Discussing Data on Efficacy and Adverse Events of Mobocertinib for NSCLC

December 05, 2022

During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.

BI 1810631 Shows Early Antitumor Activity in NSCLC

December 04, 2022

Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.

Updates Results Support Repotrectinib in ROS1+ NSCLC

December 03, 2022

Updated findings from the TRIDENT-1 suggest that repotrectinib could represent a potential new treatment option for patients with ROS1- positive advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC

December 01, 2022

"We should continue to see steady gains in new targets and improvements in our targeted therapies that make these options available for an ever-larger subgroup of patients with non–small cell lung cancer who can derive longer duration of benefit from additional lines of treatment," says H. Jack West, MD.

Pralsetinib Shows Positive Phase 1/2 Results in RET Fusion+ NSCLC

November 26, 2022

Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.

Choosing Early-Line Therapy for NSCLC With an EGFR Exon 20 Insertion

November 16, 2022

During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, discussed the case of a patient with advanced non–small cell lung cancer who had an EGFR exon 20 insertion. This is the first of 2 articles based on this event.

Reviewing Evidence for Therapies in NSCLC With EGFR Exon 20 Insertion

October 19, 2022

During a Targeted Oncology case-based roundtable discussion, Zofia Piotrowska, MD, MHS, discussed the data from clinical trials supporting mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion mutation.